Introduction
Ventricular assist devices (VADs) are a successful long-term therapy for end-stage heart failure [1, 2] . The use of biocompatible materials to construct these devices is essential. Blood contact with VADs is brief but frequent and the foreign body response towards these materials combined with heavy anti-coagulation likely contributes to VAD-associated clinical complications such as thrombosis, bleeding, and infection [3] . Surface properties of biomaterials drive the foreign body response beginning with protein adsorption, a complex process driven by different protein-surface forces such as surface energy, morphology, and ionic/electrostatic interactions [4] . The composition of the protein matrix adsorbed onto the material is highly variable but largely consists of the most abundant proteins in the blood: fibrinogen, albumin, and globulins. Platelet activation occurs through interaction with these proteins with fibrinogen in particular leading to plateletplatelet aggregation [5] These immobilised platelets are then able to recruit and activate blood borne leukocytes, mainly neutrophils and monocytes, which contribute to the building of thrombus through adhesion whilst also releasing cytokines for further recruitment to the site [6] . Interactions of T cells with this biological surface build-up can cause activation-induced cell death resulting in defective cellular immunity and susceptibility to severe infections [7] .
Adherence and activation of leukocytes at the biomaterial's surface are well described for titanium, low density polyethylene (LDPE), Pellethane®, and polytetrafluoroethylene (PTFE) using in vitro models. This evidence is provided by changes in the expression of adhesion molecules such as decreased L-selectin (CD62L) and increased CD11b expression, an increase in inflammatory cytokine concentration (e.g. TNFα, MCP-1, IL-8), and the release of reactive oxygen species [8] [9] [10] [11] [12] . A similar activation profile is also demonstrable in vivo after implantation of VADs, e.g. platelet-leukocyte aggregates and increased monocyte tissue factor expression [13] [14] [15] . Excessive leukocyte activation could underpin a diminished immune response upon infection [16, 17] ; and thrombotic leukocyte-derived microparticles [18, 19] might lead to stroke, embolism, or device replacement due to blockages.
Titanium is the biomaterial most commonly used for the VAD body [20] ; its resistance against fatigue and corrosion makes it durable for long-term implantation [21] . However, titanium can activate the coagulation system in vitro and thus be a thrombogenic material that activates leukocytes [22] . Other VAD components have been made from ruby alumina [23] , sapphire [24] , and zirconium [25] but the biocompatibility testing of these ceramic materials is limited to their applications as dental or joint implants [26, 27] . Silicon nitride could be a good candidate for use as a bearing due to its high strength and oxidation resistance [28] but its biocompatibility has been tested with osteoblasts [29] rather than blood cells. Coatings have been suggested as a solution for materials with desirable mechanical properties but poor biocompatibility. Diamond-like carbon (DLC) is a chemically inert nanocomposite coating with properties of natural diamond such as high hardness, low friction, and high corrosion resistance [30, 31] . DLC has been deemed biocompatible through prolonging clotting time, and suppressing platelet and complement activation [32] .
This study aimed to evaluate the leukocyte response to biomaterials and test a methodological approach implementable within most device development laboratories that would enable rapid evaluation of multiple biomaterials. Biomaterials that are of interest to the development of cardiovascular devices such as VADs formed the focus of this investigation: diamond-like carbon coated stainless steel (DLC), single-crystal sapphire alumina (Sap), silicon nitride (SiN), titanium alloy Ti6Al4V (Ti), and zirconia-toughened alumina (ZTA). Biomaterials were exposed to whole blood rather than isolated cells or plasma to better mimic the clinical scenario [33].
Materials and methods

Blood collection
Peripheral blood was collected from healthy adult volunteers into lithium heparin (18 I.U. lithium heparin salt per mL; Vacutainer tubes; Greiner Bio-One, Stonehouse, UK). All blood samples were collected with informed written consent. This study was approved by Wales Research Ethics Committee 6 (13/WA/0190).
Biomaterials
Highly polished discs of DLC, Sap, SiN, Ti, and ZTA (Table 1 ; SAK Equipment Ltd, East Sussex, UK) were sonicated in 3% Neutracon® (Decon Laboratories Ltd., East Sussex, UK) at +40°C for 10 min and then sonicated in warm, soapy dH2O for 3 min followed by a 3 min sonication in fresh dH2O. Discs were air-dried, sprayed with 70% denatured ethanol and left to dry on lint-free cloths.
Polypropylene beads were soaked with 70% denatured ethanol for 30 min then rinsed in sterile PBS before use.
Experimental model
Twenty polypropylene beads (2-3 mm diameter) were placed in a circle in a 70 mm petri dish (Cole Parmer, London, UK). The biomaterials were then carefully balanced on top before the addition of blood (15 mL) (Supplementary Figure 1) . Beads only served as a negative control.
Dishes were incubated at +37°C on a shaker plate set to 50 rpm. A time course was performed by sampling at 2, 4, and 8 h; the 2 h samples were deemed most appropriate to continue with for further analysis as longer incubation showed high levels of cell death and platelet activation/aggregation with little difference between biomaterials. As plasma-free haemoglobin (pfHB) can upregulate tissue factor expression on macrophages [34] haemolysis in all the samples was measured using the Harboe assay [35] to check the condition of the red blood cells before progressing to further experiments.
Complete cell counts
Total and subset cell counts were measured in triplicate using an automated haematology analyser (CELL-DYN Ruby; Abbott Diagnostics, Berkshire, UK).
Leukocyte activation, aggregation and death through flow cytometry
Leukocyte activation and death Changes in leukocyte activation -decreased L-selectin (CD62L), increased CD11b, and increased fMLP receptor -were monitored using flow cytometry. These were measured as mean (Table 2) . Red blood cells were lysed with EasyLyse (Dako, Ely, UK), and DRAQ7 (BioStatus, Leicester, UK) was used for viability monitoring without need for a wash step [36] . Whole blood stimulated with 10 ng/mL LPS for 4 h at +37°C, 5% CO2-in-air as below was used as a positive control and unstained samples were used for gating purposes. Blood exposed to 1% Triton-X 100 (Fisher Scientific, Loughborough, UK) was used to set a gate for DRAQ7 positive cells. Single-stained AbC beads (Life Technologies, Paisley, UK) were used for compensation. Samples were acquired immediately (Navios flow cytometer, Beckman Coulter) using linear forward scatter (FSC) versus side scatter (SSC) scale, flow rate set to high, and stop gate on 10,000 CD15 + events which would allow for acquisition of approximately 5,000 total lymphocytes and 1,000 monocytes. Post-acquisition compensation and data analysis were performed using Kaluza 1.3 (Beckman Coulter).
Leukocyte-platelet aggregation
The leukocyte-platelet aggregation assay was performed using CD15 and CD14 as above combined with 12.5 ng/µL CD41 (APC, clone P2, Beckman Coulter); CD41 is a platelet marker, CD15 a neutrophil marker and CD14 a monocyte marker -co-expression on an event identified using flow cytometry is indicative of aggregates containing these cells [37] . Samples were stained and lysed with a wash step included before running. Whole blood stimulated with 4 µM PMA for 20 min was used as a positive control; tubes were run on a logarithmic scale with 10,000 CD15 + events as the stopping gate.
Whole blood cultures
Whole blood cultures (50 µL blood/150 µL RPMI 1640 containing 2 mM GlutaMax and 0.1 mM 2-mercaptoethanol; Life Technologies) were left unstimulated or stimulated with 10 ng/mL E. coli OIII:B4 lipopolysaccharide (Ultrapure LPS, Invivogen, Toulouse, France) in a U-bottomed 96-well plate. After 24 h incubation at +37°C, 5% CO2-in-air cell-free supernatants were harvested by centrifugation (+4°C, 515 x g, 7 min).
L-selectin, cytokines and endotoxin levels
Levels of plasma soluble L-selectin and IL-1β, TNFα, IL-6, and IL-8 in cell culture supernatants from whole blood cultures were measured using specific ELISAs as per the manufacturer's instructions (DuoSet, R&D Systems, Oxford, UK). Presence of endotoxin was measured in unstimulated cell culture supernatants using the limulus amebocyte lysate LAL Chromogenic
Endotoxin Quantitation Kit according to manufacturer's instructions (Thermo Fisher Scientific, Loughborough, UK). 
9 Statistical analysis
Results
Condition of blood
Total erythrocyte counts in comparison to the baseline sample at time 0 (n = 16; Figure 1A ) were not significantly affected by biomaterials. Concentrations of pfHB were not significantly higher than the baseline time 0 sample (n = 9; Figure 1B ).
Leukocyte cell counts
Total leukocyte, neutrophil, and lymphocyte counts in comparison to the baseline sample at time 0 (n=16; Figure 2A , B and D) were not significantly affected by biomaterials. Monocyte counts decreased significantly upon exposure to DLC (p = 0.018), SiN (p = 0.025), and ZTA (p= 0.009) ( Figure 2C ).
Leukocyte activation and death
Expression of CD62L (n = 9) on neutrophils ( Figure 3Ai ) and lymphocytes (Supplementary Figure   S3 ) was not affected significantly by the biomaterials whereas expression of CD62L on monocytes 
Leukocyte-platelet aggregation
Aggregation of leukocytes with platelets contributes to the build-up of thrombus on the surface of materials. Neutrophil-platelet and monocyte-platelet aggregates were elevated in comparison to the baseline time 0 sample in all biomaterials but this was not significant ( Figure 4 , n = 5).
Cytokine production
The effect of exposure to biomaterials on leukocyte functionality was considered by studying the response to the prototypic inflammatory stimuli LPS using whole blood cultures after exposure to biomaterials. LPS induced a significant increase in inflammatory cytokine levels in blood exposed to biomaterials as well as control blood in keeping with the expected effects of LPS [39] . Levels of LPS-stimulated pro-inflammatory cytokines IL-8 ( Figure 5A ; n = 7), IL-1β ( Figure 5B ; n = 7), IL-6 ( Figure 5C ; n = 5) and TNFα ( Figure 5D ; n = 5) were unchanged by exposure to any of the biomaterials.
Discussion
Assessing the potential total blood damage effects of multiple biomaterials in vitro are desired to minimise adverse events in VAD patients. Our model has focused on how leukocytes respond to the VAD candidate biomaterials to quickly identify which cells are affected. Such a model might prove an effective early stage screening tool for evaluating biomaterials. The simple suspension of a disc in a petri dish can be performed by anyone and allows for full blood coverage over a large, flat, uniform surface -more representative of the implantation of a medical device than thin films, wires, and beads used by others [40] [41] [42] . Additionally, our model allows for erythrocytes, platelets, and leukocytes in whole blood to be studied simultaneously in an experimental system which is recommended by the International Standards [43] . A key feature of this model is that the assays can be used to quickly identify leukocyte subsets most susceptible to each biomaterial type and the level of activation, all of which might contribute to thrombus formation within the VAD [44].
The biomaterial discs used in this study were manufactured to have a smooth surface (Table 1) to comply with the internal surface condition of many VAD types (MicroMed DeBakey, Jarvik-2000, HeartWare HVAD) [20] and were cleaned thoroughly to reduce the presence of contaminants; endotoxin levels were below 1 EU/mL (Supplementary Figure 5) . The method was designed to allow the effects of the biomaterials to emerge without requiring complicated experimental rigs.
Initial time course analysis revealed that incubation times longer than 2 hours introduced time- The titanium alloy Ti6Al4V is the biomaterial of choice for the VAD body [20] and is therefore the largest surface area for blood contact. Titanium can be thrombogenic by promoting the formation of a surface protein matrix composed of fibrinogen, thrombin, complement factors, and coagulation cascade proteins such as kallikrein that encourages cell activation and adhesion [47] .
In this study, titanium had no significant effect on the leukocyte count, leukocyte activation/aggregation/death indicating that the surface protein matrix formed was relatively inert in terms of leukocyte activation/adhesion. Titanium has been shown to cause high levels of TNFα (~600 pg/mL) To overcome biocompatibility issues in mechanically desirable materials, coatings with excellent biocompatibility have been introduced. DLC is one such coating which rapidly adsorbs albumin and inhibits fibrinogen adsorption [30] therefore strongly reduces platelet adhesion and activation, prolongs clotting time, and suppresses complement convertase activation [32] . In this study, DLC showed a significant decrease in monocyte count with a decreased monocyte CD62L expressiona response like that of the ceramics. DLC has been shown to slightly increase monocyte adhesion
[57], with DLC coated rather than uncoated Ti6Al4V favouring cell adhesion [58] .
Due to the findings that monocytes are the key leukocyte target type, ongoing work involves optimising methods for visualising cells adhered to the biomaterial surface. A limitation of this study is the continued contact of the blood cells with the biomaterials when residence time would normally be measured in milliseconds rather than hours, and the absence of shear stress. Parallel work is considering the additive effects of biomaterials shear stress on leukocyte activation. This is being done using a rheometer and this approach has driven the size of the biomaterials discs used and the model optimised for study.
Conclusion
This simple model can be used by anyone in the blood-contacting devices field to quickly identify the cells most affected by materials of choice for better targeted research. Such research could include elucidating the mechanism of activation or careful consideration of the cells of interest during further in vitro and in vivo testing of the material. The methods used here go beyond the tests recommended by the International Standards to include a more thorough investigation of the leukocyte response, such as cytokine release. This is important when designing a device for patients with a disease characterised by haematological effects on multiple cells types. Our study has largely focused on leukocytes and shown that monocytes become activated by ceramic materials considered for bearings and DLC, the classically termed 'inert' material, but not with titanium. Such monocyte activation could contribute to the thrombus build-up which has already been observed on ceramic material bearings in current VAD designs so warrants further investigation. Overall the candidate materials studied caused little activation of healthy, human blood leukocytes. However, the target patient group of people with chronic heart failure have preexisting inflammation meaning leukocytes, particularly monocytes, are already activated [59, 60] which might render the biomaterials no longer 'inert'. This possibility has been described: platelet adherence on low and medium thrombogenic polymer-based biomaterials was increased for patients with coronary artery disease compared to healthy controls [61] . Therefore, this model also offers a simple approach to determining the effects of biomaterials leukocytes and other blood cells and proteins in blood from paediatric and adult heart failure patients to add real value to the field. Figures and Tables   Table 1. Biomaterial specifications. Surface roughness was measured using a SurfTest SJ-210 profileometer (Mitutoyo UK) Ltd., Hampshire, UK). soluble L-selectin using specific ELISA. There were no significant differences in comparison to baseline (n = 8).
Biomaterial
Supplementary Figure 5:
Endotoxin levels. Unstimulated, biomaterial-exposed-cell culture supernatants were analysed for endotoxin described in the materials and methods (n = 7). 1 EU/mL is approximately 0.1 ng endotoxin/mL.
